Carl Spana, Ph.D., President and Chief Executive Officer
Dr. Spana, co-founder of Palatin, has served as president and chief executive officer since 2000. He has been a director of Palatin since 1996 and has been a director of Palatin’s wholly-owned subsidiary, RhoMed Incorporated, since 1995. From 1996 to 2000, Dr. Spana served as an executive vice president and chief technical officer of Palatin.
From 1993 to 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From 1991 to 1993, Dr. Spana was a research associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana is a director of AVAX Technologies, Inc., a publicly-held medical technology company.
Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.
Stephen T. Wills, C.P.A., M.S.T., Chief Financial Officer and Chief Operating Officer
Mr. Wills joined Palatin as vice president and chief financial officer in 1997. He brings a depth of financial experience in public accounting and healthcare to the company.
From 1991 to 2000, Mr. Wills served as the president and chief operating officer of Golomb, Wills and Company, P.C., a public accounting firm. During that time, from 1997 to 2000, he was also the vice president and chief financial officer of Derma Sciences, Inc., a publicly-held company providing wound and skin care products. Mr. Wills is currently lead director of Derma Sciences.
Mr. Wills, a certified public accountant, earned his B.S. in accounting from West Chester University, and an M.S. in taxation from Temple University.
Jeffrey D. Edelson, M.D., M.H.Sc., Chief Medical Officer
Dr. Edelson joined Palatin as chief medical officer in 2010, and has been a consultant to the company since 2009. He is a pulmonary/critical care physician with extensive experience in product and clinical development and regulatory strategy and operations.
Dr. Edelson’s pharmaceutical industry experience includes serving as vice president of novel therapeutics at Johnson & Johnson Pharmaceutical Research and Development and prior management positions at Aventis Pharmaceuticals and SmithKline Beecham. He has also worked in leadership roles in biotech and specialty pharma firms. In 2008, he founded AEQuanimitas Consulting LLC, a pharmaceutical advisory firm, and has worked with a number of biotechnology, pharmaceutical and investment organizations.
Dr. Edelson earned his M.D. and M.H.Sc. (Master of Health Sciences) from the University of Toronto.